There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Catalyst Biosciences Inc (CBIO) and Syros Pharmaceuticals (SYRS) with bullish sentiments.
Catalyst Biosciences Inc (CBIO)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Catalyst Biosciences Inc, with a price target of $35. The company’s shares closed on Friday at $10.68, close to its 52-week low of $6.62.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 19.5% and a 50.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Logicbio Therapeutics Inc, and Adverum Biotechnologies.
Currently, the analyst consensus on Catalyst Biosciences Inc is a Moderate Buy with an average price target of $35.
See today’s analyst top recommended stocks >>
Syros Pharmaceuticals (SYRS)
In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Syros Pharmaceuticals, with a price target of $26. The company’s shares closed on Friday at $6.81, close to its 52-week low of $6.25.
Cann noted:
“The positive data presented at ASH for SY-1425 in a biomarker directed population were anticipated at ASH. The data are very positive in combination with azacitidine and daratumumab. The ORR of 63% compares very favorably to single-agent azacitidine in unfit AML patients. Results demonstrated clinical activity with a high response rate and a rapid onset of responses. We estimate that SY-1425 will account for 100% of Syros’ 2022 revenue.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 3.6% and a 42.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.75, representing a 204.7% upside. In a report released yesterday, Roth Capital also maintained a Buy rating on the stock with a $14 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
